Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Visionstate Announces Deals in Canada and the US, Highlights Growing Opportunities (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Beigene ADS Representing Ord Shs
ONC
Healthcare
Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the...
treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ONC)
New Post
View:
Posts & Comments
Threaded Posts
(294)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Dec 04, 2024 9:00pm
BeiGene and CLL Society Partner to Advance Test Before Treat
Just In: $BGNE BeiGene and CLL Society Partner to Advance Test Before Treat(TM) Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLLAbout 50% of patients with CLL/SLL have high
...more
(294)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 27, 2024 11:00am
European Commission Approves BeiGene's TEVIMBRA for First-Li
JUST IN: $BGNE European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction CancerNew
...more
(294)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 30, 2024 3:17pm
BeiGene Ltd. (NASDAQ: BGNE) Records 52-Week High Monday Morn
JUST IN: $BGNE BeiGene Ltd. (NASDAQ: BGNE) Records 52-Week High Monday MorningShares of BeiGene, Ltd. (NASDAQ: BGNE) traded at a new 52-week high today and are currently trading at $230.59. So far
...more
(294)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 26, 2024 1:02pm
BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation
NEWS: $BGNE BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLLDesignation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients
...more
(294)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 23, 2024 7:47pm
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clin
Just In: $BGNE BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World$800 million
...more
(294)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 04, 2024 4:00pm
BeiGene to Present at the Goldman Sachs 45th Annual Global H
JUST IN: $BGNE BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
LEARN about a Biotech Rising to New Heights and Transforming Regenerative Medicine
Global Tungsten Market Overview and Supply Security